Optimizing treatment in HIV/HCV coinfection

Digestive and Liver Disease

Volumn 45, Issue S5, 2013, Pages

  Puoti, Massimo ^a   Rossotti, Roberto ^a   Travi, Giovanna ^a   Panzeri, Claudia ^a   Morreale, Marco ^a   Chiari, Erika ^b   Cocca, Giorgia ^a   Orso, Maurizio ^a   Moioli, Maria Cristina ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b AO Spedali Civili ^*  (Italy)

Author keywords

Antiretroviral therapy; Boceprevir; HCV; HIV; PEG IFN; Ribavirin; Telaprevir

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; ERYTHROPOIETIN; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; TELAPREVIR; TENOFOVIR; ZIDOVUDINE;

ANEMIA; AREA UNDER THE CURVE; BLOOD TRANSFUSION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

3TC; ANTIRETROVIRAL THERAPY; AREA UNDER THE CURVE; ATAZANAVIR BOOSTED WITH RITONAVIR; ATV/R; AUC; BOC; BOCEPREVIR; CART; COMBINATION ANTI RETROVIRAL THERAPY; DARUNAVIR BOOSTED WITH RITONAVIR; DRV/R; EFAVIRENZ; EFV; EMTRICITABINE; ETR; ETRAVIRINE; FOSAMPRENAVIR; FPV/R; FTC; HCV; HEPATITIS C VIRUS; HIV; HUMAN IMMUNODEFICIENCY VIRUS; LAMIVUDINE; LOPINAVIR BOOSTED WITH RITONAVIR; LPV/R; MALE HAVING SEX WITH MALES; MSM; NEVIRAPINE; NVP; PEG-IFN; PEGINTERFERON; PERSONS LIVING WITH HIV; PLHIV; RAL; RALTEGRAVIR; RBV; RIBAVIRIN; RILIPIVIRINE; RPV; SUSTAINED VIROLOGICAL RESPONSE; SVR; TDF; TEL; TELAPREVIR; TENOFOVIR;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; OLIGOPEPTIDES; PROLINE; RIBAVIRIN;

EID: 84884717120     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.09.001     Document Type: Review

References (35)

1. Puoti M., Moioli M.C., Travi G., Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Seminars in Liver Disease 2012, 32:103-113.
2. Puoti M., Moioli M.C., Rossotti R., et al. Human immunodeficiency virus and hepatitis C virus coinfection: the agenda is full while waiting for new drugs. Hepatology 2013, 57:4-6.
3. Ioannou G.N., Bryson C.L., Weiss N.S., Miller R., Scott J.D., Boyko E.J. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013, 57:249-257.
4. Peters L., Grint D., Lundgren J.D., et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012, 26:1917-1926.
5. Lo Re V., 3rd, Volk J., Newcomb C.W., et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012, 56:1688-1698.
6. Berenguer J., Rodríguez E., Miralles P., et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clinical Infectious Diseases 2012, 55:728-736.
7. Kramer J.R., Kanwal F., Richardson P., Mei M., El-Serag H.B. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hypertension 2012, 56:320-325.
8. Carrat F., Bani-Sadr F., Pol S., et al. PEG-IFN alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Journal of the American Medical Association 2004, 292:2839-2848.
9. Voigt E., Schulz C., Klausen G., et al. PEG-IFN alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of infection 2006, 53:36-42.
10. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine 2004, 351:438-450.
11. Nunez M., Miralles C., Berdun M.A., et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Research and Human Retroviruses 2007, 23:972-982.
12. Rodriguez-Torres M., Slim J., Bhatti L., et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clinical Trials 2012, 13:142-152.
13. Laguno M., Cifuentes C., Murillas J., et al. Randomized trial comparing PEG-IFN alpha-2b versus PEG-IFN alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009, 49:22-31.
14. Berenguer J., Rodriguez E., Miralles P., et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clinical Infectious Diseases 2012, 55:728-736.
15. Labarga P., Barreiro P., da Silva A., et al. Comparison of high ribavirin induction versus standard ribavirin dosing. Plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Journal of Infectious Diseases 2012, 206:961.
16. Soriano V., Puoti M., Sulkowski M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007, 21:1073-1089.
17. Dieterich D.T., Soriano V., Sherman K., et al. Telaprevir in combination with PEG-IFN-a-2a+ribavirin in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. Conference on Retroviruses and Other Opportunistic Infections 2012, [Abstract #46].
18. Sulkowski M.S., Pol S., Cooper C., et al. Boceprevir+PEG-IFN+ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. Conference on Retroviruses and Other Opportunistic Infections 2012, [Abstract #47].
19. Cotte L., Braun J., Lascoux-Combe C., et al. High early virological response with Telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1/HIV co-infected patients: ANRS HC26 TelapreVIH Study. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #36].
20. Poizot-Martin I., Bellissant E., Piroth L., et al. ANRS-HC27 BocepreVIH interim analysis: high early virological response with Boceprevir+PEG-IFN+ribivirin in hepatitis C virus/HIV co-infected patients with previous failure to PEG-IFN + Ribivirin. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #37].
21. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
22. Fontaine H., Hezode C., Dorival C., et al. SVR12 rates and safety of triple therapy including Telaprevir or Boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). EASL 48th Annual Meeting 2013.
23. Martel-Laferriere V., Brinkley S., Bichoupan K., et al. On-treatment responses to Telaprevir-based hepatitis C treatment are similar in HIV/hepatitis C virus co-infected and hepatitis C virus mono-infected patients. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #679].
24. Kostman J., Gilmore J., Binkley A., et al. Risk of anemia in HIV/hepatitis C virus co-infected patients treated with Telaprevir-based hepatitis C virus therapy. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #677].
25. Fierer D. Telaprevir for acute hepatitis C virus in HIV+ men both shortens treatment and improves outcome. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #156LB].
26. Benito J.M., Sánchez-Parra C., Maida I., et al. Triple combination therapy for hepatitis C with Telaprevir exhibits greater early antiviral activity than with Boceprevir. Antiviral Therapy 2013, http://www.ncbi.nlm.nih.gov/pubmed/?term=Benito+JM%2C+.+Triple+combination+therapy+503+for+hepatitis+C+with+Telaprevir+exhibits+greater+early+antiviral+activity+than+504+Q4+with+Boceprevir.+505+Antiviral+Therapy+2013, [Epub ahead of print]. 10.3851/IMP2614.
27. Burger D., Back D., Buggisch P., et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. Journal of Hypertension 2012, 58:792-800.
28. Wilby K.J., Greanya E.D., Ford J.A., Yoshida E.M., Partovi N. A review of drug interactions with Boceprevir and Telaprevir: implications for HIV and transplant patients. Annals of Hepatology 2012, 11:179-185.
29. Rhee E., Feng H.-P., Xuan F., et al. Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor Boceprevir and HIV-1 NNRTI rilpivirine. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #537].
30. Puoti M., Rossotti R., Travi G., et al. Top topics in HCV research arena. BMC Infectious Diseases 2012, 12(Suppl. 2):S7.
31. Dieterich D., Rockstroh J., Orkin C., et al. Simeprevir with PEG-IFN/ribavirin in patients co-infected with chronic hepatitis C Virus and HIV-1: week-24 interim analysis of the TMC435-C212 study. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #154LB].
32. Dieterich D., Sorian2 V., Nelson M., et al. STARTVerso 4: high rates of early virological response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + PEG-IFN and ribavirin. Conference on Retroviruses and Other Opportunistic Infections 2013, [Abstract #40LB].
33. Rodriguez-Torres M., Milagros Gonzales M., Rodriguez J., et al. HIV/HCV coinfected and HCV monoinfected patients have similar early hepatitis C viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF). 52nd ICAAC interscience conference on antimicrobial agents and chemotherapy 2012.
34. Pilot study to assess the efficacy of and tolerance to a quadruple therapy to treat HIV-HCV coinfected patients previously null responders (QUADRIH). (Last visit 08.05.13); 2013. http://www.clinicaltrials.gov/ct2/show/NCT01725542%3Fterm=asunaprevir+daclatasvir+hiv%26rank=1.
35. Niederau C., Hüppe D., Zehnter E., et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World Journal of Gastroenterology 2012, 18:1339-1347.